Study on Safety and Performance of AdvanCore Bone Void Filler

Not Applicable

Not yet recruiting

• Conditions: Bone Fractures; Bone Defects; Bone Loss; Bone Graft

• Registration Number: NCT06736457
• Lead Sponsor: Artur Salgado SA

Brief Summary

The objective of this study is to evaluate the safety and performance of AdvanCore implantable bone graft through a 12-month follow-up period in a prospective, parallel-group design, non-controlled, open label, multi-center and real-world setting study. This study is intended to satisfy post-market clinical follow-up requirements of CE Mark in Europe.

Detailed Description

AdvanCore is a porous beta-tricalcium phosphate CE-marked medical device. It is intended to be used to aid in the bone regeneration process in situations where bone is damaged beyond the limits of its self-healing ability. The target population is constituted by adult subjects in need of bone grafting of mechanically unaffected, pathologic, or traumatic bone defects caused by surgery or trauma.

AdvanCore is produced in the shape of blocks, wedges, or granules in different sizes and is surgically placed into spaces between or around broken bone (fractures) or in holes (defects). The site to be augmented must be free from infection and free from soft or granulation tissue. AdvanCore must contact cancelous bone and may be pressed into the defect area by hand or shaped more accurately to fit the area. It can be used as is, impregnated with subjects' blood/ bone marrow and/ or mixed with medicinal substances under the responsibility of the qualified professionals.

AdvanCore acts as a temporary scaffold and is not intended to provide mechanical support during the healing process. Additional therapy for load-bearing (such as osteosynthesis) is indicated if the bone does not comply with the required biomechanical function.

The study on safety and performance of AdvanCore bone void filler will be conducted in European sites and include up to 190 subjects requiring bone implant surgery, which will be divided in 3 different groups:

* Group 1- This group is formed by those subjects with long-bone injuries. The treatment of this type of lesion may be performed using blocks, wedges, or granules.

* Group 2- Subjects included in this group suffer from spine injuries, which can be treated using granules.

* Group 3- Those subjects with maxillofacial injuries are included in this group. In this case, granules are used to treat the lesion.

The primary safety endpoint of this study is defined as freedom of bone reintervention due to AdvanCore usage at 6 months, analyzing the occurrence of Adverse Events or Serious Adverse Events \[(S)AEs\] related to the device usage and/ or AdvanCore procedure that may lead to subjects' reoperation.

The primary performance endpoint will analyze the AdvanCore osteointegration after 6 months of surgery, studying the percentage of subjects with successful osteointegration at the defined time point. AdvanCore will be considered successfully osteointegrated when no presence of fibrotic tissue surrounding the implant is detected.

Secondary endpoints planned for this clinical investigation are listed below:

* Evaluation of (S)AEs related to the procedure;

* Evaluation of (S)AEs related to the device;

* Freedom of reintervention due to AdvanCore usage;

* AdvanCore osteointegration;

* AdvanCore resorption rate, assessed as the percentage of subjects with successful bone graft resorption.

The clinical investigation has been designed to involve as little pain, discomfort, fear, and any other foreseeable risk as possible for subjects.

Study Timeline

• Status Verified: 2024-12
• Study First Submitted: 2024-12-11
• Study First Submitted QC: 2024-12-13
• Last Update Submitted: 2024-12-13
• Study First Posted: 2024-12-16
• Last Update Posted: 2024-12-16
• Study Start: 2025-03-01
• Primary Completion: 2025-10
• Study Completion: 2026-09

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 190

Inclusion Criteria

• Adult subjects ≥ 18 years old, male or female.
• Subjects who are eligible for a bone grafting/bone void filler procedure.
• Subjects with bone lesions beyond the limits of the bone's self-healing ability.
• Subjects, and/or an authorized representative, who are willing and capable of providing informed consent, participating in all testing associated with this clinical investigation at an approved clinical investigational center.
• Subjects with only one fracture susceptible to treatment with an AdvanCore implant.

Exclusion Criteria

• Subjects with any AdvanCore contraindication for implantation or use.
• Subjects with hypersensitivity to any of the AdvanCore components.
• Subjects with infections or soft/granulation tissue in the area to place bone graft.
• Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study.
• Women who are breastfeeding or of childbearing potential who are, or plan to become, pregnant during the time of the study (method of assessment upon physician's discretion).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Freedom of bone reintervention (safety)	6 months post-surgery	The primary safety endpoint is defined as freedom of bone reintervention due to AdvanCore usage at 6 months, analyzing the occurrence of (S)AEs related to the device usage and/ or AdvanCore procedure that may lead to subjects' reoperation.
Successful osteointegration (performance)	6 months post-surgery	The primary performance endpoint will analyze the AdvanCore integration at 6 months of surgery. This process is defined as osteointegration, which refers to the direct structural and functional connection of the living bone with the surface of the implant. The implant osteointegration will be assessed by imaging techniques selected according to the current clinical practices of each site. In this regard, the primary performance endpoint will be analyzed by considering the percentage of subjects with successful osteointegration at the defined timeline. AdvanCore will be considered successfully osteointegrated when the presence of fibrotic tissue surrounding the implant is not detected.

Secondary Outcome Measures

Name	Time	Method
Evaluation of Adverse Events or Serious Adverse Events [(S)AEs] related to the procedure (safety)	30-days post-surgery	Record of Adverse Events or Serious Adverse Events \[(S)AEs\] related to the procedure during a 12-month follow-up period. In all cases, the analysis population will be the Per-Protocol population, and results will be presented as the incidence (in percentage) of (S)AEs, with a 95% confidence.
Evaluation of (S)AEs related to the procedure (safety)	12 months post-surgery	Record of (S)AEs related to the procedure during a 12-month follow-up period. In all cases, the analysis population will be the Per-Protocol population, and results will be presented as the incidence (in percentage) of (S)AEs, with a 95% confidence.
Evaluation of (S)AEs related to the device (safety)	12 months post-surgery	Record of (S)AEs related to the device during a 12-month follow-up period. In all cases, the analysis population will be the Per-Protocol population, and results will be presented as the incidence (in percentage) of (S)AEs, with a 95% confidence.
Freedom of reintervention (safety)	12 months post-surgery	Freedom of reintervention due to AdvanCore usage, analyzing the occurrence of (S)AEs related to the device usage and/ or AdvanCore procedure that may lead to subjects' reoperation.
Successful osteointegration (performance)	12 months post-surgery	The implant osteointegration will be assessed by imaging techniques selected according to the current clinical practices of each site. This analysis will determine the percentage of number of subjects with successful implant osteointegration. AdvanCore will be considered successfully osteointegrated when the presence of fibrotic tissue surrounding the implant is not detected.
Successful resorption (performance)	12 months post-surgery	Resorption is the breakdown and assimilation of the implant in the cycle of bone growth. The implant resorption will be assessed by imaging techniques selected according to the current clinical practices of each site. This analysis will determine the percentage of number of subjects with successful implant resorption. The successful resorption rate will be reached if at least 50% of the AdvanCore graft cannot be detected at 12 months.

Trial Locations

Locations (4)

Unidade Local de Saúde do Alto Ave; 🇵🇹 Guimarães, Braga, Portugal

Unidade Local de Saúde do Médio Tejo; 🇵🇹 Tomar, Santarém, Portugal

Unidade Local de Saúde de Trás-os-Montes e Alto Douro; 🇵🇹 Lordelo, Vila Real, Portugal

Unidade Local de Saúde de São João; 🇵🇹 Porto, Portugal